Triple
T18768563
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Celestron |
E458953
|
entity |
| Predicate | parentOrganization |
P254
|
FINISHED |
| Object | Synta Technology Corporation |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Synta Technology Corporation | Statement: [Celestron, parentOrganization, Synta Technology Corporation]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Synta Technology Corporation Context triple: [Celestron, parentOrganization, Synta Technology Corporation]
-
A.
Millennium Pharmaceuticals
Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
-
B.
Hargreave-Rasch Biotechnologies
Hargreave-Rasch Biotechnologies is a fictional advanced biotech corporation in the Crysis video game universe, known for its cutting-edge research into alien technology and military applications.
-
C.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
-
D.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
E.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Synta Technology Corporation Target entity description: Synta Technology Corporation is a Taiwanese manufacturer and global supplier of optical instruments, best known as the owner and producer behind the Celestron brand of telescopes and astronomy equipment.
-
A.
Millennium Pharmaceuticals
Millennium Pharmaceuticals is a biotechnology company known for developing innovative cancer therapies, including the proteasome inhibitor bortezomib (Velcade) for multiple myeloma.
-
B.
Hargreave-Rasch Biotechnologies
Hargreave-Rasch Biotechnologies is a fictional advanced biotech corporation in the Crysis video game universe, known for its cutting-edge research into alien technology and military applications.
-
C.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
-
D.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
E.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8d395dba0819087568404508590cb |
completed | April 10, 2026, 10:40 a.m. |
| NER | Named-entity recognition | batch_69e58d867264819098ae35c9feab3bb4 |
completed | April 20, 2026, 2:20 a.m. |
Created at: April 10, 2026, 11:52 a.m.